跳到內容

跳到副選單

耶和華見證人

中文繁體(國語)

輸血替代療法的效益

血液科——腫瘤醫學

Budget impact analysis on erythropoiesis-stimulating agents use for the management of chemotherapy-induced anaemia in Greece.

Nikolaidi E, Hatzikou M, Geitona M.

出處‎: Cost Eff Resour Alloc 2013;11(1):16.

檢索‎: PubMed 23870502

DOI碼‎: 10.1186/1478-7547-11-16

http://www.ncbi.nlm.nih.gov/pubmed/23870502

The burden of blood transfusion: a utilization and economic analysis--a pilot study in patients with chemotherapy-induced anemia (CIA).

Reitan JF, Kudrik FJ, Fox K, van Breda A, Shreay S, Corey-Lisle PK.

出處‎: J Med Econ 2013;16(5):633-8.

檢索‎: PubMed 23425291

DOI碼‎: 10.3111/13696998.2013.778269

http://www.ncbi.nlm.nih.gov/pubmed/23425291

Hemoglobin level at initiation of darbepoetin alfa: impact on need for transfusion and associated costs in chemotherapy-induced anemia treatment in Europe.

Deger M, Eisterer W, Kutikova L, Salek S.

出處‎: Support Care Cancer 2013;21(2):485-93.

檢索‎: PubMed 22825456

DOI碼‎: 10.1007/s00520-012-1538-0

http://www.ncbi.nlm.nih.gov/pubmed/22825456

Prospective study of erythropoietin use on quality of life and cost effectiveness in acute myeloid leukemia and allogeneic hematopoietic stem cell transplantation patients.

Michallet M, Goldet K, Sobh M, Morisset S, Chelghoum Y, Thomas X, Barraco F, Ducastelle S, Labussière H, Renzullo C, Paillet C, Pivot C, Straaten PB, Denis A, Termoz A, Detrait M, Nicolini FE, Jaisson-Hot I.

出處‎: Cancer 2013;119(1):107-14.

檢索‎: PubMed 22744794

DOI碼‎: 10.1002/cncr.27686

http://www.ncbi.nlm.nih.gov/pubmed/22744794

Impact of a conservative red blood cell transfusion strategy in children undergoing hematopoietic stem cell transplantation.

Lightdale JR, Randolph AG, Tran CM, Jiang H, Colon A, Houlahan K, Billet A, Sloan S, Lehmann LE.

出處‎: Biol Blood Marrow Transplant 2012;18(5):813-7.

檢索‎: PubMed 22080050

DOI碼‎: 10.1016/j.bbmt.2011.10.043

http://www.ncbi.nlm.nih.gov/pubmed/22080050

Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia.

Pashos CL, Larholt K, Fraser KA, McKenzie RS, Senbetta M, Piech CT.

出處‎: Support Care Cancer 2012;20(1):159-65.

檢索‎: PubMed 21359879

DOI碼‎: 10.1007/s00520-010-1083-7

http://www.ncbi.nlm.nih.gov/pubmed/21359879

Modeling the cost-effectiveness of prothrombin complex concentrate compared with fresh frozen plasma in emergency warfarin reversal in the United Kingdom.

Guest JF, Watson HG, Limaye S.

出處‎: Clin Ther 2010;32(14):2478-93.

檢索‎: PubMed 21353116

DOI碼‎: 10.1016/j.clinthera.2011.01.011

http://www.ncbi.nlm.nih.gov/pubmed/21353116

Cost-effectiveness of hydroxyurea in reducing the frequency of pain episodes and hospitalization in pediatric sickle cell disease.

Stallworth JR, Jerrell JM, Tripathi A.

出處‎: Am J Hematol 2010;85(10):795-7.

檢索‎: PubMed 20645429

DOI碼‎: 10.1002/ajh.21772

http://www.ncbi.nlm.nih.gov/pubmed/20645429

Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction.

Sarode R, Refaai MA, Matevosyan K, Burner JD, Hampton S, Rutherford C.

出處‎: Transfusion 2010;50(2):487-92.

檢索‎: PubMed 19804569

DOI碼‎: 10.1111/j.1537-2995.2009.02413.x

http://www.ncbi.nlm.nih.gov/pubmed/19804569

The cost-effectiveness of treatment with erythropoietin compared to red blood cell transfusions for patients with chemotherapy induced anaemia: a Markov model.

Borg S, Glenngård AH, Osterborg A, Persson U.

出處‎: Acta Oncol 2008;47(6):1009-17.

檢索‎: PubMed 18770060

DOI碼‎: 10.1080/02841860701744498

http://www.ncbi.nlm.nih.gov/pubmed/18770060

Should intravenous iron be the standard of care in oncology?

Auerbach M.

出處‎: J Clin Oncol 2008;26(10):1579-81.

檢索‎: PubMed 18375888

DOI碼‎: 10.1200/JCO.2007.15.4609

http://www.ncbi.nlm.nih.gov/pubmed/18375888

Cost of outpatient blood transfusion in cancer patients.

Crémieux PY, Barrett B, Anderson K, Slavin MB.

出處‎: J Clin Oncol 2000;18(14):2755-61.

檢索‎: PubMed 10894876

http://www.ncbi.nlm.nih.gov/pubmed/10894876


JW.ORG​網站​內​的​醫療​資訊​主要​是​提供​給​醫生​及​醫療人員​參考,而​不​是​要​提供​診斷​建議​或​推薦​某​種​醫療​方法,也​不​是​要​取代​專業​的​醫療​護理。網站​上​引用​的​許多​醫學​文章​都​不​是​耶和華見證人​出版​的,但​當​中​提​到​了​許多​替代​輸​血​的​療法,這些​醫療​策略​很​值得​醫生​參考。每​一​個​專業​醫療人員​都​有​責任​經常​吸收​最​新​的​醫療​資訊,討論​最​適合​病人​的​醫療​方法。他們​也​要​根據​病人​的​病情、意願、價值觀​和​信仰​來​協助​病人​選擇​最佳​的​醫療​方式。本​網站​所​提供​的​醫療​策略​不​一定​適用​於​每​一​個​病人。

給​病人​的​建議:當​你​感到​身體​不適,要​立刻​尋求​醫生​的​幫助,也​要​聽取​醫生​以及​其他​專業​醫療人員​的​建議。

使用​本​網站​即​表示​你​接受​本使用​條款的​全部​內容。